Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 23, 2022 03:01 ET | Source: Tyler Prize

Prestigious Environmental Prize Awarded to World Expert on the Links Between Climate Change and Human Health

LOS ANGELES, Feb. 23, 2022 (GLOBE NEWSWIRE) -- The 2022 Tyler Prize for Environmental Achievement – often regarded as the ‘Nobel Prize for the Environment’ – has been awarded to British physician...
February 22, 2022 05:23 ET | Source: Research and Markets

Global Biobanking Market Trends and Forecasts to 2026: Growing Focus on Mainstream Precision Medicine and Rise of Genomic Medicine/Clinical Genomics

Dublin, Feb. 22, 2022 (GLOBE NEWSWIRE) -- The "Biobanking: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. This report aims to provide a comprehensive...
January 14, 2022 04:08 ET | Source: Research and Markets

Global Pharma and Biotech Preclinical Stage Partnering Deals Directory 2021: Comprehensive Access to Deals and Contract Documents for Over 2,400 Deals

Dublin, Jan. 14, 2022 (GLOBE NEWSWIRE) -- The "Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021" report has been added to ResearchAndMarkets.com's offering. ...
January 06, 2022 09:00 ET | Source: Aceragen

Aceragen Announces $3.5 Million Development Award from Cystic Fibrosis Foundation to Progress Novel Therapy for CF-Related Exacerbations

Raleigh-Durhan, NC, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aceragen, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for orphan diseases with high unmet medical need, today...
January 05, 2022 09:00 ET | Source: Aceragen

Aceragen’s wholly-owned subsidiary, Arrevus, awarded $45 million funding agreement from the Department of Defense’s Defense Threat Reduction Agency for Development of ACG-701 as Medical Countermeasure Against Melioidosis

Raleigh-Durham, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Arrevus, Inc., a clinical-stage biopharmaceutical company developing therapies for orphan infectious diseases with high unmet medical need, ...
November 10, 2021 04:03 ET | Source: Research and Markets

Insights on Pharma, Biotech & Diagnostics Industry from 2015 to 2021

Dublin, Nov. 10, 2021 (GLOBE NEWSWIRE) -- The "Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2015-2021" report has been added to ResearchAndMarkets.com's...
August 09, 2021 08:30 ET | Source: ProPhase Labs, Inc.

ProPhase Labs to Host Second Quarter 2021 Financial Results Conference Call on Friday, August 13, 2021 at 11:00 a.m. Eastern Time

GARDEN CITY, NY , Aug. 09, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, will hold a conference call on Friday, August 13, 2021...
March 30, 2021 17:10 ET | Source: ProPhase Labs, Inc.

ProPhase Labs Acquires Digital Covid Vaccination and Testing “Passport” Solution

New Reporting App Simplifies Documentation of User Vaccination and Covid Testing Statue – Easily Enables Clear Access to Air/Rail/Bus Travel, Concert & Sporting Events GARDEN CITY, NY, March...
March 15, 2021 08:30 ET | Source: ProPhase Labs, Inc.

ProPhase Labs to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Wednesday, March 31, 2021 at 4:30 p.m. Eastern Time

GARDEN CITY, NY, March 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, will hold a conference call on Wednesday, March 31, 2021...
January 29, 2021 08:30 ET | Source: ProPhase Labs, Inc.

ProPhase Labs Announces Opening of Large CLIA Lab Covid Testing Facility in Garden City, New York

- Total Company Processing Capacity On Track to Reach 60,000 Tests Per Day – GARDEN CITY, NY, Jan. 29, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical...

keyboard_arrow_left Previous Page